4 Dec 2014 16:27
4 December 2014
Immunodiagnostic Systems Holdings Plc ("IDS" or "the Company" or the "Group")
Director's share sale
Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of diagnostic testing kits and automated systems for the clinical and research markets, announces that the Company was informed on 4 December 2014 that Patrik Dahlen sold the following shares on 2 and 3 December 2014:
Number of shares sold
| Share price (1) | Resultant holding | Resultant % | |
Patrik Dahlen | 44,751 | 323p | 0 | 0.0% |
(1) Average share price
For further information:
Immunodiagnostic Systems Holdings PLC | Tel : +44 (0)191 519 0660 |
Patrik Dahlen, Chief Executive Officer | |
Chris Yates, Finance Director
| |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel
| |
FTI Consulting |
Tel : +44 (0)207 831 3113 |
Ben Atwell |
About Immunodiagnostic Systems Holdings PLC
The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally, the Group is focused on developing an endocrinology excellence menu and externally, IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.
http://www.idsplc.com
IDH.L (IDH)